Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin A - Merz Pharma

Drug Profile

Botulinum toxin A - Merz Pharma

Alternative Names: Botulinum neurotoxin type A free from complexing proteins (NT 201) - Merz Pharmaceuticals; Incobotulinum toxin A; NT-201; Xeomin

Latest Information Update: 25 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BIOTECON Therapeutics
  • Developer Merz Pharma; Merz Pharmaceuticals GmbH; Yale University
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Skin disorder therapies; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Dystonia; Glabellar lines; Muscle spasticity; Sialorrhoea; Torticollis
  • Phase III Atrial fibrillation
  • Phase II Essential tremor; Trigeminal neuralgia
  • No development reported Pain
  • Discontinued Cancer pain

Most Recent Events

  • 30 Sep 2019 Phase-III clinical trials in Atrial fibrillation (Prevention) in France (Parenteral) (NCT04075981)
  • 16 Sep 2019 Merz Pharmaceuticals initiates a phase III PATTERN trial for Muscle spasticity (In adolescents, In adults) (Lower limb spasticity in patients with cerebral palsy) in Czech Republic, Germany, Poland and Spain (IM) (NCT03992404)
  • 02 Sep 2019 Merz Pharmaceuticals plans a phase III trial for Atrial fibrillation (Prevention) in France in September 2019 (NCT04075981)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top